Literature DB >> 12576797

Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Pia Bader1, Fiona C Burkhard, Regula Markwalder, Urs E Studer.   

Abstract

PURPOSE: In prostate cancer involvement of regional lymph nodes is regarded as a poor prognostic factor. Is this also true for micrometastasis if a meticulous lymph node dissection is performed? We determined progression rate and survival of patients with positive nodes following radical prostatectomy according to the number of metastases.
MATERIALS AND METHODS: Between 1989 and 1999, 367 patients with clinically organ confined prostate cancer underwent meticulous pelvic lymph node dissection and radical prostatectomy. None of the patients received immediate adjuvant therapy.
RESULTS: Of the patients 92 (25%) had histologically proven lymph node metastases. Followup of more than 1 year was available in 88 patients (96%), and median followup was 45 months (range 13 to 141). Of 19 patients (22%) who died of prostate cancer 16 had more than 1 positive node. Of the 39 patients with only 1 positive node 15 (39%) remained without signs of clinical or chemical progression. Whereas of the 20 and 29 patients with 2 or more positive lymph nodes only 2 (10%) and 4 (14%), respectively, remained disease-free. Time to prostate specific antigen relapse, symptomatic progression and tumor related death were significantly affected by the number of positive nodes.
CONCLUSIONS: Meticulous lymph node dissection reveals a high rate of metastases (25%). In patients with positive nodes time to progression is significantly correlated with the number of diseased nodes. Some patients with minimal metastatic disease remain free of prostate specific antigen relapse for more than 10 years after prostatectomy without any adjuvant treatment. Meticulous pelvic lymph node dissection, particularly in patients with micrometastases, seems not only to be a staging procedure, but may also have a positive impact on disease progression and long-term disease-free survival.

Entities:  

Mesh:

Year:  2003        PMID: 12576797     DOI: 10.1097/01.ju.0000049032.38743.c7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  108 in total

1.  [Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system].

Authors:  P G Hammerer; H Augustin; J Blonski; M Graefen; A Haese; A Erbersdobler; F Daghofer; H Huland
Journal:  Urologe A       Date:  2004-03       Impact factor: 0.639

2.  Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy.

Authors:  Michele Lodde; Louis Lacombe; Angelo Naselli; Paolo Puppo; Michael Mian; Yves Fradet
Journal:  World J Urol       Date:  2012-01-24       Impact factor: 4.226

Review 3.  [Treatment of locally advanced prostate cancer].

Authors:  M P Wirth; O W Hakenberg; M Fröhner
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

Review 4.  [The role of pelvic lymphadenectomy in clinically localised prostate cancer].

Authors:  M Schumacher; F C Burkhard; U E Studer
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

5.  The emergence of radioimmunoscintigraphy for prostate cancer.

Authors:  Thomas E Keane; Inger L Rosner; M Scott Wingo; David G McLeod
Journal:  Rev Urol       Date:  2006

6.  Radical Prostatectomy and Pelvic Lymph Node Dissection in Kaiser Permanente Southern California: 15-Year Experience.

Authors:  Pooya Banapour; Andrew Schumacher; Jane C Lin; David S Finley
Journal:  Perm J       Date:  2019

Review 7.  Contemporary management of patients with penile cancer and lymph node metastasis.

Authors:  Andrew Leone; Gregory J Diorio; Curtis Pettaway; Viraj Master; Philippe E Spiess
Journal:  Nat Rev Urol       Date:  2017-04-11       Impact factor: 14.432

8.  Determination of adequate pelvic lymph node dissection range for Japanese males undergoing radical prostatectomy.

Authors:  Nobuki Furubayashi; Takahito Negishi; Hidenori Iwai; Kei Nagase; Kenichi Taguchi; Mototsugu Shimokawa; Motonobu Nakamura
Journal:  Mol Clin Oncol       Date:  2017-03-28

Review 9.  Concept and viability of androgen annihilation for advanced prostate cancer.

Authors:  James L Mohler
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

10.  [Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions].

Authors:  D Weckermann; M Hamm; R Dorn; T Wagner; F Wawroschek; R Harzmann
Journal:  Urologe A       Date:  2006-06       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.